Semaglutide and Ozempic (the brand of semaglutide FDA-approved for the treatment of type 2 diabetes) were the most mentioned products, while Wegovy (the brand of semaglutide FDA-approved for the treatment of obesity), tirzepatide, Mounjaro (the brand of tirzepatide FDA-approved for the treatment of type 2 diabetes), Zepbound (the brand of tirzepatide FDA-approved for the treatment of obesity), and the overall GLP-1 RA class were discussed less often, reflecting the public’s attention to Ozempic as a prominent GLP-1 RA agent and the first medication receiving market approval. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.